Drugs / HTI-1090
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03491631 | Nov 2018 → Jun 2023 | metastatic malignant neoplasm | Jiangsu HengRui Medicine Co., Ltd. | Unknown | No outcome recorded |
| Phase 1 | NCT03208959 | Aug 2017 → Nov 2018 | cancer | Atridia Pty Ltd. | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HTI-1090 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03208959 ↗ |
| Known as | SHR9146 | “HTI-1090 (also referred as SHR9146 in nonclinical study reports)” NCT03208959 ↗ |
| Action | Inhibit | “a small molecule that inhibits both indoleamine 2,3-dioxygenase 1 (IDO1) and tryptophan 2,3-dioxygenase (TDO)” NCT03208959 ↗ |
| Modality | Small molecule | “a small molecule that inhibits both indoleamine 2,3-dioxygenase 1 (IDO1) and tryptophan 2,3-dioxygenase (TDO)” NCT03208959 ↗ |
| Route | Oral | “HTI-1090 tablets will be orally administered” NCT03208959 ↗ |
| Target | IDO1 | “a small molecule that inhibits both indoleamine 2,3-dioxygenase 1 (IDO1) and tryptophan 2,3-dioxygenase (TDO)” NCT03208959 ↗ |